This analysis examines Dr Lal PathLabs (LALPATHLAB) through the lens of its financial statements, valuation metrics, and institutional ownership patterns.
Lal PathLabs Revenue Trend
The top line tells a positive story: Dr Lal PathLabs's revenue advanced 7.2% to ₹2,461 Cr in FY2025.
Over the past 10 years, revenue has grown at a healthy 14.1% CAGR, from ₹660 Cr to ₹2,461 Cr. That's solid, above-average growth.
At ₹2,461 Cr in annual revenue, Dr Lal PathLabs is one of the mid-sized players in the healthcare space.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹2,461 Cr | +7.2% |
| FY2024 | ₹2,296 Cr | +11.5% |
| FY2023 | ₹2,059 Cr | -3.8% |
| FY2022 | ₹2,140 Cr | +31.1% |
| FY2021 | ₹1,633 Cr | — |
View Dr Lal PathLabs's full 10-year revenue trend with CAGR analysis →
Lal PathLabs Profitability
Bottom-line growth was evident, with Dr Lal PathLabs posting ₹487 Cr in net profit for FY2025 — up 34.5% from ₹362 Cr.
Net margin widened to 19.8% in FY2025 — an improvement from the 15.8% recorded in FY2024.
Diluted EPS stood at ₹29.20 in FY2025, compared to ₹21.49 in FY2024.
Is Lal PathLabs Undervalued
The P/E Ratio valuation pegs Dr Lal PathLabs's fair value at ₹1,845, which is 17.5% upside from the current price.
Dr Lal PathLabs shares are currently trading at ₹1,569.60.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,845 | 17.5% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Dr Lal PathLabs with detailed assumptions →
Lal PathLabs Shareholding Pattern
The promoter stake has come down from 53.8% to 53.2%, which bears watching.
FII ownership stands at 17.2%, down from the 21.7% recorded a year ago.
DII ownership is at 21.4%, up from the 17.9% recorded a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 53.2% | 17.2% | 21.4% | 7.9% |
| Dec 2025 | 53.2% | 20.3% | 19.2% | 6.9% |
| Sep 2025 | 53.2% | 21.9% | 18.5% | 6.1% |
| Jun 2025 | 53.8% | 21.7% | 17.9% | 6.2% |
Track quarterly shareholding changes for Dr Lal PathLabs →
Lal PathLabs Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹27.17B at the end of FY2025, up 10.6% from ₹24.56B a year earlier.
Other Assets is the largest block at 35.7%, followed by Intangibles & Goodwill at 29.4% and Cash & ST Investments at 22.8%.
Equity makes up 81.2% of liabilities and equity, with debt at 5.8% and operating liabilities at 13.0%. Over the year, debt is down 36.2% and equity is up 17.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 6.19B |
| Receivables | 881.21M |
| Inventories | 361.32M |
| Property, Plant & Equipment | 2.04B |
| Intangibles & Goodwill | 7.99B |
| Other Assets | 9.70B |
| Category | Value |
|---|---|
| Equity | 22.06B |
| Short-term Debt | 547.94M |
| Long-term Debt | 1.03B |
| Trade Payables | 1.99B |
| Other Liabilities | 1.54B |
Lal PathLabs Key Highlights
To sum up Dr Lal PathLabs's financial position: the data paints a clear picture for investors evaluating this healthcare stock.
Revenue of ₹2,461 Cr in FY2025, up 7.2% year-over-year.
Long-term revenue has been compounding at 14.1% annually over 10 years.
The company is profitable, with a net margin of 19.8% and net income of ₹487 Cr.
The P/E Ratio model implies 17.5% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Dr Lal PathLabs's detailed profile on Craytheon.